IRIS
MARCHICA, VALENTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.268
EU - Europa 1.151
AS - Asia 486
AF - Africa 21
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 1
Totale 2.933
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.252
CN - Cina 343
SE - Svezia 290
IE - Irlanda 289
IT - Italia 257
DE - Germania 90
TR - Turchia 68
FI - Finlandia 57
AT - Austria 51
SG - Singapore 50
CZ - Repubblica Ceca 21
RO - Romania 20
CI - Costa d'Avorio 16
FR - Francia 16
CA - Canada 15
IN - India 15
BE - Belgio 13
GB - Regno Unito 11
NL - Olanda 8
UA - Ucraina 7
EU - Europa 6
ES - Italia 5
RU - Federazione Russa 4
BG - Bulgaria 3
IR - Iran 3
LU - Lussemburgo 3
SC - Seychelles 3
IL - Israele 2
KH - Cambogia 2
NG - Nigeria 2
SM - San Marino 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
BN - Brunei Darussalam 1
BZ - Belize 1
CH - Svizzera 1
DK - Danimarca 1
HK - Hong Kong 1
MD - Moldavia 1
RS - Serbia 1
Totale 2.933
Salva come PNG Salva come JPEG
Città #
Chandler 333
Dublin 286
Parma 116
Ashburn 115
Ann Arbor 93
Shanghai 90
Dearborn 67
New York 57
Izmir 54
Nanjing 51
Vienna 51
Beijing 46
Princeton 45
Wilmington 27
Singapore 24
Bremen 23
Shenyang 23
Helsinki 22
Los Angeles 20
Boardman 19
Brno 18
Abidjan 16
San Mateo 15
Hebei 14
Brussels 13
Jinan 13
Kunming 13
Nanchang 13
Kocaeli 12
Milan 11
Focsani 10
Modena 10
Redmond 10
Bologna 8
Fairfield 8
Houston 8
Jiaxing 8
Munich 8
Toronto 8
Woodbridge 8
Changsha 7
Hefei 7
Norwalk 7
Guangzhou 6
Pune 6
Savignano sul Rubicone 6
Tianjin 6
Washington 6
Zhengzhou 6
Des Moines 5
Düsseldorf 5
Hangzhou 5
Jacksonville 5
Madrid 5
Palermo 5
Rho 5
Seattle 5
Rio Saliceto 4
Romainville 4
Rome 4
Torino 4
Ahmedabad 3
Cesena 3
Fremont 3
Gorgonzola 3
London 3
Lviv 3
Nürnberg 3
Ottawa 3
Redwood City 3
Reggio Emilia 3
San Giuliano Milanese 3
Sofia 3
St Louis 3
Amsterdam 2
Arcevia 2
Borås 2
Cento 2
Chengdu 2
Cornaredo 2
Deiva Marina 2
Edinburgh 2
Florence 2
Grafing 2
Lagos 2
Luxembourg 2
Manchester 2
Marseille 2
Medesano 2
Montreal 2
Phnom Penh 2
Piacenza 2
Pilastro 2
Sabz 2
Santa Clara 2
Taiyuan 2
Taizhou 2
Tampa 2
Tel Aviv 2
Turin 2
Totale 1.990
Salva come PNG Salva come JPEG
Nome #
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 97
Neurofibromatosis type I and multiple myeloma coexistence: A possible link? 91
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 88
Application of next-generation sequencing for the genomic characterization of patients with smoldering myeloma 82
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 81
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 79
Novel targets for the treatment of relapsing multiple myeloma 79
Possible targets to treat myeloma-related osteoclastogenesis 78
Oncolytic virotherapy and microenvironment in multiple myeloma 77
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 76
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 76
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 76
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 76
Bone Marrow DKK-1 Levels in Smoldering Multiple Myeloma Patients: A New Independent Risk Factor for Progression 73
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 73
A simplified sars-cov-2 pseudovirus neutralization assay 71
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 70
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 69
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 67
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 66
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 65
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 65
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma 63
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 63
Amlexanox inhibition of TBK1/IKK epsilon Signaling Is a Novel Therapeutic Approach for Multiple Myeloma-Induced Bone Disease. 62
Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses 61
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 60
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 59
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy 58
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma 56
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 56
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin? 55
Lenalidomide Increases Human Dendritic Cell Maturation in Multiple Myeloma Modulating Both Monocyte Differentiation and Mesenchymal Stromal Cell Inhibitory Properties through Ikaros and Casein Kinase 1 Degradation, Respectively 55
Concomitant primary hyperparathyroidism in patients with multiple myeloma: A possible link? 52
Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets 52
Role of Galectins in Multiple Myeloma. 51
The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4 51
PD-L1/PD-1 axis in multiple myeloma microenvironment and a possible link with CD38-mediated immune-suppression 51
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma 51
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies 49
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 48
Transcriptional and proteomic profiles of bone marrow CD14+ cells in multiple myeloma (MM) compared to smoldering MM and MGUS: overexpression of Interleukin (IL)-21 receptor and its involvement in MM-induced osteoclastogenesis 47
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors 45
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories 42
MYELOMA CELLS FROM THE BONE MARROW TO THE SKIN: HOW? 38
The impact of CD56 expression in smoldering myeloma patients on early progression 36
Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma 26
Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease 22
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response 21
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4) 20
Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma 12
Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma 7
Totale 3.044
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.222
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.222
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020350 77 56 8 8 13 58 46 8 24 36 10 6
2020/2021250 30 4 7 7 40 8 15 22 44 28 16 29
2021/2022296 6 10 10 23 6 7 43 35 26 15 19 96
2022/20231.244 129 141 92 100 102 137 50 81 340 14 45 13
2023/2024540 22 43 14 14 37 160 49 11 24 43 26 97
2024/202525 25 0 0 0 0 0 0 0 0 0 0 0
Totale 3.044